Natco faces regulatory heat in India over anticancer
This article was originally published in Scrip
The drugs controller general of India, Dr Surinder Singh, is said to be mulling legal action against Natco Pharma for selling a "substandard" drug, Albupax (paclitaxel in an albumin bound nanoparticle form), which has already allegedly failed certain endotoxin tests.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.